JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis

Albumin is an attractive candidate carrier for the development of novel therapeutic drugs. Gemcitabine has been FDA approved for the treatment of solid tumors; however, new drugs that optimize gemcitabine delivery are not available for clinical use. The aim of this study was to test the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Tiantian, Corrales-Guerrero, Sergio, Castro-Aceituno, Veronica, Nair, Sindhu, Maneval, Daniel C., Monnig, Curtis, Kearney, Patrick, Ellis, Sam, Raheja, Nicholas, Raheja, Neil, Williams, Terence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477748/
https://www.ncbi.nlm.nih.gov/pubmed/37674628
http://dx.doi.org/10.1016/j.omto.2023.08.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477748/
https://www.ncbi.nlm.nih.gov/pubmed/37674628
http://dx.doi.org/10.1016/j.omto.2023.08.008

Ejemplares similares